

## Special Issue

# State-of-the-Art Vaccine Researches

### Message from the Guest Editors

mRNA vaccine took the center of the scene and represented a game changer for the speed of response to pandemic, however several question marks remain in regards to durability of response and breadth of applicability to bacterial targets. In parallel, extensive and fast growing knowledge was established for novel platforms like protein nanoparticles and viral vectors for DNA delivery as well as for more traditional ones like recombinant proteins and glycoconjugates. Finally, innovative adjuvant systems and alternative delivery were largely investigated to improve the magnitude and quality of the immune response induced by vaccination. This special issue is focused on recent scientific knowledge and current state of the art technologies. Based on your extensive experience, we invite you to contribute with an original research to highlight: novel data obtained with state of the art technologies; comparison of different vaccine platforms in terms of the resulting immunogenicity; innovative combination of vaccine antigens in high-valency formulations, and strategies to maximize immune responses against vaccine targets through alternative delivery and adjuvant systems.

---

### Guest Editors

Dr. Omar Rossi

Dr. Gianmarco Gasperini

Dr. Carlos Giannelli

---

### Deadline for manuscript submissions

closed (1 November 2024)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/131653](https://mdpi.com/si/131653)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).